Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01VLQ
|
||||
Former ID |
DNC000032
|
||||
Drug Name |
15-hydroxyeicosatetraenoic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1], [2] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C20H32O3
|
||||
Canonical SMILES |
CCCCCC(CCCCCC=CC=CC=CC=CC(=O)O)O
|
||||
InChI |
1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-6,8,10,12,15,18-19,21H,2-3,7,9,11,13-14,16-17H2,1H3,(H,22,23)/b5-4+,8-6+,12-10+,18-15+
|
||||
InChIKey |
GQHZVWMHPQXBIA-QYANQBPOSA-N
|
||||
CAS Number |
CAS 136194-77-9
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
ChEBI ID |
ChEBI:51913
|
||||
Target and Pathway | |||||
Target(s) | Arachidonate 5-lipoxygenase | Target Info | Inhibitor | [1], [2] | |
BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
Resolvin D biosynthesis | |||||
Leukotriene biosynthesis | |||||
Lipoxin biosynthesis | |||||
Aspirin triggered resolvin D biosynthesis | |||||
Aspirin triggered resolvin E biosynthesis | |||||
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Toxoplasmosis | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
WikiPathways | Vitamin D Receptor Pathway | ||||
Arachidonic acid metabolism | |||||
Eicosanoid Synthesis | |||||
Selenium Micronutrient Network | |||||
References | |||||
REF 1 | Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. | ||||
REF 2 | Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein. J Biol Chem. 1998 Dec 4;273(49):32842-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.